Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Prostate Cancer
100%
Partial Nephrectomy
97%
Prostatectomy
89%
Recurrent Disease
72%
Transitional Cell Carcinoma
66%
Bladder
65%
Diseases
65%
Kidney Tumour
61%
Cystectomy
59%
Tumor
54%
Clear Cell Renal Cell Carcinoma
52%
Nephrectomy
52%
Pelvis
49%
Ureter Obstruction
46%
Surgeon
46%
Neoplasm
45%
Ureteroscopy
42%
Cancer
42%
Surgical Margin
41%
Blood Transfusion
39%
Biopsy Technique
38%
Postoperative Complication
38%
Robot-Assisted Prostatectomy
37%
Chemotherapy
37%
Prostate Specific Antigen
36%
Muscle Invasive Bladder Cancer
35%
Urologist
35%
Ex Vivo
34%
Prostate Biopsy
34%
Endometriosis
34%
Bladder Cancer
33%
Percutaneous Nephrostomy
32%
Malignant Neoplasm
31%
Surgery
30%
Neoadjuvant Chemotherapy
30%
Treatment Outcome
30%
Magnetic Resonance Imaging
30%
Disease Specific Survival
30%
Computer Assisted Tomography
29%
Histology
29%
Transurethral Resection
29%
Prostate Specific Membrane Antigen
28%
Biochemical Recurrence
28%
Holmium
27%
Positron Emission Tomography-Computed Tomography
27%
Urinary System
26%
Overall Survival
25%
Cancer Specific Survival
24%
Radiation Therapy
24%
Metastatic Carcinoma
24%
Keyphrases
Renal Cell Carcinoma
64%
Radical Prostatectomy
60%
Partial Nephrectomy
54%
Upper Tract Urothelial Carcinoma
49%
Malignancy
47%
Prostate Cancer
43%
Tumor
41%
Prostate
40%
Nephrectomy
36%
Endoscopic Management
34%
Malignant Ureteric Obstruction
34%
Perioperative Blood Transfusion
34%
In-bore
34%
Kidney
34%
Ureteroscopy
31%
Operative Time
31%
Bladder
30%
Prostate-specific Antigen
29%
Cancer Patients
28%
Percutaneous Nephrostomy
27%
Non-muscle Invasive Bladder Cancer (NMIBC)
27%
Radical Cystectomy
27%
Oncological Outcomes
27%
Positron Emission Tomography/computed Tomography (PET/CT)
26%
Disease-specific Survival
24%
Ureteral Stent
24%
Renal Mass
24%
Laparoscopic Partial Nephrectomy
24%
Radical Nephrectomy
23%
Local Recurrence
23%
Prostate Biopsy
23%
Bone Scan
23%
Tandem Ureteral Stent
23%
Autonomous Cortisol Secretion
23%
Prostate-specific Membrane Antigen
23%
Laparoscopic Surgical Robot
23%
Cancer-specific Survival
22%
Prostate-specific Membrane Antigen Positron Emission Tomography
21%
Replication Timing
21%
Urinary Tract
20%
Ureter
20%
Surgeons
20%
Postoperative Outcomes
19%
Overall Survival
19%
Endoscopic Treatment
19%
Nomogram
19%
Urologists
19%
Peripheral Blood Lymphocytes
19%
Clinical Outcomes
18%
Length of Stay
18%